NKGen Biotech reports sustained cognitive improvement in single Alzheimer's patient treated with troculeucel
NKGN•NKGen Biotech said one patient's condition improved from moderate to mild Alzheimer's within three months of treatment with investigational troculeucel, with improvement maintained through 24 months of cumulative treatment. No treatment-related adverse events were reported; an interim analysis of an ongoing Phase 2a trial is expected in the second half of 2027.
1. Patient observations
NKGen Biotech presented long-term observations of investigational Alzheimer's therapy troculeucel in one patient at the CTAD 2026 conference. The patient's condition improved from moderate to mild Alzheimer's within three months, and the improvement was maintained through 24 months of cumulative treatment. No treatment-related adverse events were reported during either treatment period.
2. Trial underway
The single-patient findings cannot establish efficacy. An ongoing randomized, placebo-controlled Phase 2a trial has an interim analysis expected in the second half of 2027.




